Früherkennung versus Vorsorge bei Hochrisikopatientinnen für Brust- und Eierstockkrebs

Kernaussagen

Bei Verdacht auf genetisch bedingten Brust- bzw. Eierstockkrebs sollte eine genetische Beratung angeboten werden. Die Mutationsanalytik sollte nur bei Erfüllung der Kriterien auf Wunsch der Ratsuchenden durchgeführt werden, wobei der Ratsuchenden Strategien zur Bewältigung möglicher Befunde angeboten und erklärt werden sollen. Neben psychologischer Unterstützung sind das v. a. die Früherkennung und die Prophylaxe.

Den Ratsuchenden müssen explizit die Vor- und Nachteile der jeweiligen Strategie verdeutlicht werden. Erst durch ausreichende Information kann sich die Ratsuchende für ihren persönlichen Weg entscheiden (Informed Consent).

• Literatur

• 1 King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302 (5645) 643-646
• 2 Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408
• 3 Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-1333
• 4 Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689
• 5 Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000; 83: 1301-1308
• 6 Satagopan JM, Boyd J, Kauff ND et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8: 3776-3781
• 7 Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-414
• 8 Deutsche S3 Leitlinie, Interdisziplinäre S3 Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 3.0, 2012.
• 9 Singer CF, Tea MK, Pristauz G et al. Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families. Wien Klin Wochenschr 2012; 124: 334-339
• 10 Antoniou AC, Hardy R, Walker L et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008; 45: 425-431
• 11 Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. J Am Med Assoc 2004; 292: 1317-1325
• 12 Passaperuma K, Warner E, Causer PA et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012; 107: 24-30
• 13 Lord SJ, Lei W, Craft P et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007; 43: 1905-1917
• 14 Lee JM, McMahon PM, Kong CY et al. Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers. Radiology 2010; 254: 793-800
• 15 Plevritis SK, Kurian AW, Sigal BM et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. J Am Med Assoc 2006; 295: 2374-2384
• 16 Smith-Warner SA, Spiegelman D, Yaun SS et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. J Am Med Assoc 1998; 279: 535-540
• 17 Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer 2010; 46: 2593-2604
• 18 McTiernan A, Irwin M, Vongruenigen V. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol 2010; 28: 4074-4080
• 19 Iodice S, Barile M, Rotmensz N et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010; 46: 2275-2284
• 20 Schmidt C. The breast cancer chemoprevention debate. J Natl Cancer Inst 2011; 103: 1646-1647
• 21 Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 1876-1881
• 22 Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87
• 23 Eisen A, Lubinski J, Klijn J et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23: 7491-7496
• 24 Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055-1062